Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Complement C3 Antibody (F1-8), mFluor Violet 450 SE, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP246609MFV450
Description
Complement C3 Monoclonal antibody specifically detects Complement C3 in Human samples. It is validated for ELISA, Immunoprecipitation, Affinity PurificationSpecifications
| Complement C3 | |
| Monoclonal | |
| mFluor Violet 450 SE | |
| 50mM Sodium Borate | |
| Mouse | |
| Protein A or G purified | |
| RUO | |
| Primary | |
| Human | |
| Purified |
| ELISA, Immunoprecipitation, Affinity Purification | |
| F1-8 | |
| ELISA, Immunoprecipitation, Immunoaffinity Purification | |
| Acylation Stimulating Protein, acylation-stimulating protein cleavage product, AHUS5, ARMD9, ASP, C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3a, C3a anaphylatoxin, C3adesArg, C3b, C3bc, C3-beta-c, complement C3, Complement C3 alpha chain, Complement C3 beta chain, Complement C3b alpha' chain, Complement C3c alpha' chain fragment 1, Complement C3c alpha' chain fragment 2, Complement C3d fragment, Complement C3dg fragment, Complement C3f fragment, Complement C3g fragment, complement component 3, complement component C3, complement component C3a, complement component C3b, CPAMD1, EC 3.4.21.43, epididymis secretory sperm binding protein Li 62p, HEL-S-62p, prepro-C3 | |
| This Complement C3 Antibody (F1-8) was developed against Complement component 3 (C3) purified from human plasma. | |
| 0.1 mL | |
| Angiogenesis, Apoptosis, Autoimmune Diseases, Immunology, Inflammation, Innate Immunity, Mesenchymal Stem Cell Markers, Neurodegeneration, Neuroscience, Signal Transduction | |
| 718 | |
| Store at 4C in the dark. | |
| IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction